This nonrandomized controlled trial assesses the feasibility of using a circulating tumor DNA−guided adaptive de-escalation tyrosine kinase inhibitor strategy in patients with advanced non−small cell lung cancer to achieve complete remission after local consolidative therapy.
Circulating Tumor DNA-Guided De-Escalation Targeted Therapy for Advanced Lung Cancer
Leggi →
Luglio 2024